All In Biotech

Drug Trial Radar · NCT07514858

A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Trial of Lu AF28996 in Adults With Parkinson's Disease Experiencing Motor Fluctuations

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jul 28, 2026

Primary completion

Oct 3, 2028

Study completion Oct 3, 2028

Sponsor

Lead sponsor
H. Lundbeck A/SIndustry
Sponsor type
Industry
First posted
Apr 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate the effects of Lu AF28996 in adults with Parkinson's disease (PD) experiencing motor fluctuations despite optimized non-invasive symptomatic treatment. These are individuals with PD who take medications to control movement symptoms, such as slowness, stiffness, and tremor, but still experience periods of time when their medication does not adequately control their motor symptoms. Some may also experience dyskinesia (other type of involuntary movements) as a side effect of their PD medications. The main goal of the trial is to learn whether adding Lu AF28996 to participants' optimized PD medications will help extending the time they spend with their movement symptoms being well-controlled and without bothersome dyskinesia.

Conditions

  • Parkinson's Disease

Interventions

  • Lu AF28996Drug

    Lu AF28996 will be administered orally per schedule specified in the arm description.

  • PlaceboDrug

    Placebo matching to Lu AF28996 will be administered orally per schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 19 in Daily Good ON Time Based on the Participant's Hauser Diary EntriesTime frame: Baseline, Week 19

Locations

6 sites in 4 countries. Site status is shown where the registry gives one.

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida · Recruiting

  • QUEST Research Institute

    Farmington, Michigan · Recruiting

  • Central Texas Neurology Consultants (CTNC)

    Round Rock, Texas · Recruiting

  • Praglandia s.r.o.

    Prague, Praha, Hlavni Mesto, Czechia · Recruiting

  • Curiositas Ad Sanum - Haag In Oberbayern

    Haag I.Ob, Bavaria, Germany · Recruiting

  • European Trial group network Sp. z o.o - Neuroscience

    Warsaw, Masovian Voivodeship, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.